Health ❯Healthcare ❯Pharmaceuticals

Drug Development

Clinical Trials Alzheimer's Disease Eli Lilly Obesity Treatments Monoclonal Antibodies Novo Nordisk Combination Therapy Weight Loss Drugs Obesity Treatment Antibody-Drug Conjugates

Teva’s Olanzapine LAI Shows No PDSS in Phase 3 SOLARIS Long-Term Data Presented at Psych Congress

The company now targets an H2 2025 NDA following data that showed class-consistent safety with maintained symptom control.

FDA Clears Shot Version of Keytruda as EU Panel Backs Approval

CHMP Backs Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

AstraZeneca’s Fasenra Misses Primary Endpoint in COPD Phase III Trial

Eye Drops Pairing Pilocarpine and Diclofenac Improve Near Vision for Up to Two Years

FDA Publishes Draft Guidance for Non-Opioid Analgesics to Treat Chronic Pain

City of Hope Launches National Clinical Trial Network to Expand Access to Cancer Treatments

Orexin-2 Agonists Lift Wakefulness in Narcolepsy as Takeda Leads With Late-Stage Wins

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

Scripps Maps Human Proteins SARS-CoV-2 Exploits, Identifying Drug Targets With Preclinical Support

Phase 3 Trial Shows Baxdrostat Lowers Blood Pressure by About 10 mmHg in Hard-to-Control Hypertension

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

FDA Launches Coordinated Pathway to Review Therapies for Ultra-Rare Genetic Diseases

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

Repurposed Drugs Clear Dormant Breast Cancer Cells in Phase II Trial

Baxdrostat Lowers Blood Pressure in Hard-to-Treat Patients in Phase III Trial